Related Experiment Video
Updated: Mar 24, 2026
Author Spotlight: Generating Neuronal Phenotypic Profiles - A Protocol to Culture and Image Human Midbrain Dopaminergic Neurons
Published on: July 7, 2023
microRNA Profiles in Parkinson's Disease Prefrontal Cortex
Andrew G Hoss1, Adam Labadorf2, Thomas G Beach3
1Department of Neurology, Boston University School of MedicineBoston, MA, USA; Graduate Program in Genetics and Genomics, Boston University School of MedicineBoston, MA, USA.
Objective:
The goal of this study was to compare the microRNA (miRNA) profile of Parkinson's disease (PD) frontal cortex with normal control brain, allowing for the identification of PD specific signatures as well as study the disease-related phenotypes of onset age and dementia.
Methods:
Small RNA sequence analysis was performed from prefrontal cortex for 29 PD samples and 33 control samples. After sample QC, normalization and batch correction, linear regression was employed to identify miRNAs altered in PD, and a PD classifier was developed using weighted voting class prediction. The relationship of miRNA levels to onset age and PD with dementia (PDD) was also characterized in case-only analyses.
Results:
One twenty five miRNAs were differentially expressed in PD at a genome-wide level of significance (FDR q < 0.05). A set of 29 miRNAs classified PD from non-diseased brain (93.9% specificity, 96.6% sensitivity). The majority of differentially expressed miRNAs (105/125) showed an ordinal relationship from control, to PD without dementia (PDN), to PDD. Among PD brains, 36 miRNAs classified PDD from PDN (sensitivity = 81.2%, specificity = 88.9%). Among differentially expressed miRNAs, miR-10b-5p had a positive association with onset age (q = 4.7e-2).
Conclusions:
Based on cortical miRNA levels, PD brains were accurately classified from non-diseased brains. Additionally, the PDD miRNA profile exhibited a more severe pattern of alteration among those differentially expressed in PD. To evaluate the clinical utility of miRNAs as potential clinical biomarkers, further characterization and testing of brain-related miRNA alterations in peripheral biofluids is warranted.
Insights
Parkinson's disease (PD) brains show distinct microRNA (miRNA) profiles compared to controls, with specific miRNAs classifying PD and its dementia subtype. These findings highlight potential biomarkers for PD progression.
Area of Science:
- Neuroscience
- Genetics
- Biomarker Discovery
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder with complex pathophysiology.
- MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and are implicated in various diseases, including PD.
Purpose of the Study:
- To compare the miRNA profile of the frontal cortex in Parkinson's disease (PD) patients with that of normal controls.
- To identify PD-specific miRNA signatures.
- To investigate the relationship between miRNA levels and disease phenotypes such as age of onset and dementia.
Main Methods:
- Small RNA sequencing was performed on prefrontal cortex samples from 29 PD patients and 33 controls.
- Data underwent quality control, normalization, and batch correction.
- Linear regression identified differentially expressed miRNAs, and a classifier was built using weighted voting.
- Case-only analyses examined miRNA associations with age of onset and PD with dementia (PDD).
Main Results:
- 125 miRNAs were significantly differentially expressed in PD brains (FDR q < 0.05).
- A panel of 29 miRNAs accurately classified PD from non-diseased brains (96.6% sensitivity, 93.9% specificity).
- A pattern of miRNA alteration correlated with disease severity (control < PD without dementia < PDD).
- 36 miRNAs distinguished PDD from PD without dementia (81.2% sensitivity, 88.9% specificity).
- miR-10b-5p showed a positive association with age of onset in PD patients.
Conclusions:
- Cortical miRNA profiles can accurately classify PD brains.
- PDD exhibits a more pronounced miRNA alteration pattern compared to PD without dementia.
- Further research into brain-derived miRNA alterations in peripheral biofluids is needed to assess their clinical utility as biomarkers.
Related Concept Videos
01:37Neural Regulation
01:15Parkinson's Disease: Overview
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...